Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 5/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3494577 | 0.91 | KMT2A (0.49) | KMT2AMEN1ALDH1A1HPGDTSHR | |
| SCHEMBL22289272 | 0.82 | HPGD (0.49) | KMT2AMEN1ALDH1A1HPGDTSHR | |
| SCHEMBL13402898 | 0.80 | ALDH1A1 (0.49) | ALDH1A1HPGDTSHRLMNANPC1 | |
| SCHEMBL13402902 | 0.79 | POLB (0.45) | KMT2AMEN1ALDH1A1HPGDTSHR | |
| SCHEMBL13402915 | 0.78 | CYP2D6 (0.48) | ALDH1A1HPGDTSHRLMNAKDM4E | |
| SCHEMBL2662991 | 0.78 | L3MBTL1 (0.63) | ALDH1A1HPGDTSHRLMNANPC1 | |
| SCHEMBL2652440 | 0.77 | HPGD (0.44) | KMT2AMEN1ALDH1A1HPGDTSHR | |
| SCHEMBL22870155 | 0.75 | KMT2A (0.46) | KMT2AMEN1ALDH1A1HPGDTSHR | |
| SCHEMBL29088422 | 0.75 | KMT2A (0.46) | KMT2AMEN1ALDH1A1HPGDTSHR | |
| SCHEMBL3494662 | 0.75 | HPGD (0.48) | KMT2AMEN1ALDH1A1HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100081652-A1 | Cinnamoyl Compound and Use Thereof | SHIRAKI HIROAKI | 2010-04-01 | — | — | US | disclosed |
| EP-1857455-A1 | CINNAMOYL COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2007-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081652-A1 | Cinnamoyl Compound and Use Thereof | COL2A1, MMP7, COL14A1 | KMT2A 4362/4885MEN1 2870/4885ALDH1A1 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.